Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide plus fotemustine AGT modulation study in metastatic melanoma
2006-002168-24Phase 2Terminated
- Sponsor
- European Institute of Oncology
- Start
- Nov 2006
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of temozolomide and fotemustine in melanoma (2 arms), sponsored by European Institute of Oncology. Primary endpoints: Maximum tolerated dose of temozolomide plus fotemustine and Objective response rate. Started Nov 2006; status: terminated.
02
Drugs
temozolomidefotemustine
03
Conditions
melanoma
Beyond the preview
Go deeper on 2006-002168-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002168-24.